Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Alterity Therapeutics Limited ATHE

Healthcare Biotechnology
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase... see more

Current News (NDAQ:ATHE)

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

GlobeNewswire March 30, 2026

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

GlobeNewswire March 9, 2026

Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

GlobeNewswire March 4, 2026

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

GlobeNewswire March 2, 2026

Alterity Therapeutics: Appendix 4C - Q2 FY26 Quarterly Cash Flow Report & Corporate Update

GlobeNewswire January 30, 2026

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

GlobeNewswire January 21, 2026

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

GlobeNewswire November 12, 2025

Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System

GlobeNewswire November 10, 2025

Alterity Therapeutics: Appendix 4C - Q1 FY26 Quarterly Cash Flow Report

GlobeNewswire October 31, 2025
View More News ››

Opinion & Analysis (NDAQ:ATHE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ATHE)

It's a beautiful day in the neighbourhood and

This stock is performing well for us shareholders.
coolfooldumbguy - January 30, 2025

Buy buddy buy because it's taking off this morning.

And furthermore you guys will be left behind.Wow
coolfooldumbguy - January 30, 2025

This company will be brought out

By a major, their drugs will be valued in the 100's of billions 
Biomed4077 - July 2, 2021

RE:RE:RE:+170% on the day.

My bad didn't realise those were old posts...still wondering why the spike and retreat today
1MTFSA - February 2, 2021

RE:RE:+170% on the day.

Why did it collapse? Closed up 1.74%
1MTFSA - February 2, 2021

RE:it was a buy today for me

I bought today also , crazy volume , low float. Was this cross trading ?
fortunetelller - June 30, 2020
View more Bullboard ››

Desert Gold Ventures Inc.

Desert Gold Ventures Inc.

Desert Gold Ventures Inc., an exploration stage company, engages in the acquisition, exploration, and development of mineral ...
View More »

Podcasts